Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs

Background: There are potential conflicts between authorities and companies to fund new premium priced drugs especially where there are effectiveness, safety and/or budget concerns. Dabigatran, a new oral anticoagulant for the prevention of stroke in patients with non-valvular atrial fibrillation (A...

Descripción completa

Detalles Bibliográficos
Autores principales: Godman, Brian, Malmström, Rickard E., Diogene, Eduardo, Jayathissa, Sisira, McTaggart, Stuart, Cars, Thomas, Alvarez-Madrazo, Samantha, Baumgärtel, Christoph, Brzezinska, Anna, Bucsics, Anna, Campbell, Stephen, Eriksson, Irene, Finlayson, Alexander, Fürst, Jurij, Garuoliene, Kristina, Gutiérrez-Ibarluzea, Iñaki, Hviding, Krystyna, Herholz, Harald, Joppi, Roberta, Kalaba, Marija, Laius, Ott, Malinowska, Kamila, Pedersen, Hanne B., Markovic-Pekovic, Vanda, Piessnegger, Jutta, Selke, Gisbert, Sermet, Catherine, Spillane, Susan, Tomek, Dominik, Vončina, Luka, Vlahović-Palčevski, Vera, Wale, Janet, Wladysiuk, Magdalena, van Woerkom, Menno, Zara, Corinne, Gustafsson, Lars L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2014
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4050532/
https://www.ncbi.nlm.nih.gov/pubmed/24959145
http://dx.doi.org/10.3389/fphar.2014.00109

Ejemplares similares

Ejemplares similares